Abstract
Purpose: Many comorbidities, including depression, anxiety, and insomnia, occur in patients with chronic obstructive pulmonary disease (COPD). These patients may be prescribed benzodiazepines (BZDs). However, there are some concerns that benzodiazepines increase the risk of drug overdose, hypercapnic respiratory failure, acute exacerbation and increased mortality. The aim of our study was to evaluate the drug safety of BZDs in patients with COPD. Methods: We used the National Health Insurance Research database in Taiwan from 2002 to 2016 to perform a retrospective cohort study. We enrolled patients who were exposed to the first prescription of BZDs, non-BZDs or a combination (mix user) after COPD diagnosis. We performed 1:1:1 propensity score matching in three groups. The outcomes were COPD with acute exacerbation and all-cause mortality. Poisson regression analysis was performed to evaluate the incidence rate ratios for the outcomes in the groups. Results: After propensity score matching, there were 2,856 patients in each group. After adjusting for confounding factors, we found that compared to BZD users, non-BZD and mix users had nonsignificant differences in outpatient management of acute exacerbations, hospitalization management of acute exacerbations, emergency department management of acute exacerbations and all-cause mortality. BZD and mix groups showed significantly increased admission for acute exacerbation of COPD compared with that of the nonuser group, with IRRs of 2.52 (95% CI, 1.52-4.18; p = 0.0004) and 2.63 (95% CI, 1.57-4.40; p = 0.0002), respectively. Conclusion: BZD, non-BZD, and mix users showed increased COPD-related respiratory events compared to nonusers in Asian subjects.
Introduction
Patients with Chronic Obstructive Pulmonary Disease (COPD) frequently experience comorbidities such as anxiety, depression, and insomnia. To manage these symptoms, clinicians often prescribe benzodiazepines (BZDs) for their sedative and anxiolytic properties. However, BZDs are known respiratory depressants that can reduce muscle strength and blunt the ventilatory response to hypoxia and hypercapnia—a significant concern for patients with already compromised lung function.
While newer "non-BZD" receptor agonists (often called "Z-drugs" like zolpidem) were hoped to be safer due to more selective GABA receptor binding, evidence in Asian populations has been limited. This study investigates the respiratory safety and mortality risks associated with BZDs and non-BZDs in a large cohort of COPD patients in Taiwan.
Methods
This retrospective cohort study utilized the Taiwan National Health Insurance Research Database (NHIRD), which covers nearly the entire population of Taiwan. The researchers identified a massive initial cohort of over 1.8 million patients newly diagnosed with COPD between 2002 and 2015.
To minimize selection bias and balance baseline characteristics, the study employed 1:1:1 Propensity Score Matching (PSM). This resulted in three comparable groups of 2,856 patients each: BZD users, non-BZD users, and "mix" users (those using both). The primary outcomes measured were acute COPD exacerbations (outpatient, ER, and hospitalizations) and all-cause mortality.
Key Results
The study's findings suggest that the perceived safety advantage of non-BZDs over traditional BZDs is marginal at best.
Comparative Risks Among Sedative Users
When comparing the three matched groups, non-BZD users showed a slightly lower risk of outpatient-managed exacerbations compared to BZD users (IRR 0.85 at 60 days, p = 0.0226). However, this difference became non-significant as the follow-up period extended to 90, 180, and 365 days. Crucially, there were no significant differences between BZD, non-BZD, and mix users regarding the more severe outcomes of hospitalization or emergency department visits for acute exacerbations.
Comparison to Non-Users
The most striking data emerged from the sensitivity analysis comparing sedative users to non-users. Any use of these medications was associated with a dramatic increase in respiratory complications. Specifically, BZD users had a 2.52-fold increased risk of hospital admission for acute exacerbation compared to non-users. Mix users faced a similarly elevated risk (IRR 2.63).
The Mortality Paradox
Interestingly, the study observed lower all-cause mortality among sedative users compared to non-users (IRRs ranging from 0.43 to 0.56). The authors hypothesize this could be due to a "healthy user effect" or the potential that treating severe insomnia and distress provides a survival benefit that offsets the respiratory risks, though this remains a point of debate.
Discussion and Conclusion
The study highlights a critical safety concern: while non-BZDs might offer a slight benefit in reducing mild exacerbations compared to BZDs, both classes significantly elevate the risk of severe respiratory events in COPD patients. The risk is particularly high during the first 30 to 60 days of treatment initiation.
Limitations: The study relied on administrative data, lacking clinical specifics like smoking status, BMI, and lung function (FEV1) scores. Additionally, prescription data does not guarantee patient adherence.
Conclusion: In Asian patients with COPD, the use of BZDs, non-BZDs, or a combination thereof is linked to a significant increase in serious respiratory events compared to non-use. Clinicians should exercise extreme caution when prescribing these sedatives to COPD patients, prioritizing close monitoring especially during the initial phase of treatment.
Summary updated